ViiV Healthcare, a GlaxoSmithKline subsidiary, announced that the FDA has granted its injectable cabotegravir breakthrough therapy designation to prevent HIV. The status was granted based on data from a Phase IIb/III trial that showed cabotegravir being 66% more effective than the oral combo of emtricitabine, tenofovir disoproxil fumarate for HIV prevention.
Cabotegravir gains breakthrough therapy tag to prevent HIV
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.